NanoViricides President Dr. Diwan was an Invited Participant at the Prestigious CEO Roundtable
July 23 2014 - 7:00AM
Business Wire
NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) reports
that its President, Dr. Anil Diwan, was invited to participate in
the 29th Annual Chief Executive of the Year Gala Reception &
Dinner held at the New York Stock Exchange on Thursday, July 17,
2014. In addition, he was also invited to participate in the CEO
Roundtable Discussion, on the topic of “Enhancing CEO Effectiveness
by Redefining the Role of the CFO”, which was held prior to the
Reception, from 4pm to 5:50pm.
The “CEO Roundtable Discussion” was moderated by Mr. J.P.
Donlon, Editor-in-Chief, Chief Executive Magazine, with Ms. Arleen
Thomas, Senior Vice President, AICPA, serving as an Expert Advisor.
Participants included Fortune 500 Chief Executives, led by Mr.
David Cote, CEO of Honeywell, Inc., and peers drawn from successful
businesses representing industry segments from Manufacturing,
Services, Technology, Operations, to Biopharma and Healthcare.
Dr. Diwan discussed the special skills that the CFO of a typical
pre-revenue Biotech/Biopharma Company needs to possess. He
commented that the CFO of such a company needs to develop
particular expertise in strategies and tactics to be employed in an
R&D-intensive setting, keeping in mind that not all of the
R&D pays off, and that not all of the R&D has a specific
project allocability. In this situation, the role of the CFO needs
to be to help the CEO and the President with the assessment of the
impact of various R&D strategies and financing requirements,
taken together, on generating long term success for the Company,
and thereby generating long term value for the investors.
Mr. Bob Iger, Chairman and CEO of the Walt Disney Company, was
named the “2014 CEO of the Year” by the Chief Executive Magazine,
and felicitated at an invitation-only Gala Reception and Dinner
event hosted by NYSE Euronext and the Chief Executive Group at the
New York Stock Exchange on July 17, 2014. CEO of the Year is an
honor bestowed upon an outstanding corporate leader, nominated and
selected by a group of CEO peers
(http://www.marketwatch.com/story/bob-iger-chairman-and-ceo-the-walt-disney-company-is-named-2014-ceo-of-the-year-by-chief-executive-magazine-2014-07-14).
About Chief Executive Group
Chief Executive Group produces Chief Executive magazine
(published since 1977), and chiefexecutive.net, including
e-newsletters and online content, as well as conferences and
roundtables that enable top corporate officers to discuss key
subjects and share their experiences within a community of peers.
The Group also facilitates the annual "CEO of the Year," a
prestigious honor bestowed upon an outstanding corporate leader,
nominated and selected by a group of peers. Visit
www.chiefexecutive.net for more information.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating
special purpose nanomaterials for viral therapy. The Company's
novel nanoviricide® class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although
it is not possible to predict or identify all such factors, they
may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective;
successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
NanoViricides, Inc.Amanda Schuon, 310-550-7200info@nanoviricides.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jul 2023 to Jul 2024